Immune response to a recombinant hepatitis B vaccine in hemodialysis patients.
Int J Artif Organs
; 13(7): 451-3, 1990 Jul.
Article
em En
| MEDLINE
| ID: mdl-2144846
ABSTRACT
A 20-microgram dose of a recombinant hepatitis B vaccine was given at 0, 1, 2 and 6 months to 24 hemodialysis patients. From month 7 (i.e., 1 month after the fourth injection), 58.3% (14/24) of the patients had developed protective levels of antibodies against hepatitis B surface antigen (anti-HBs). In patients responding to vaccination, the fourth injection led to an abrupt rise of the anti-HBs titres which reached their maximum 2 months later, that is, in month 8. At that time, the geometric mean titre of anti-HBs was 145.79 mlU/ml. Eighteen months after the start of vaccination, 50% (12/24) of the patients were maintaining protective levels of anti-HBs antibodies. It is noteworthy that these results could be obtained with a considerably lower dosage than previously recommended.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Vacinas
/
Vacinas contra Hepatite Viral
/
Vacinas Sintéticas
/
Diálise Renal
/
Vacinação
/
Hepatite B
Limite:
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Ano de publicação:
1990
Tipo de documento:
Article